CMG PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,060 KRW | -0.24% |
|
-1.20% | -14.52% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2022 | 2023 |
|---|---|---|---|---|
| Capitalization 1 | 461,137 | 590,292 | 298,618 | 334,730 |
| Enterprise Value (EV) 1 | 406,673 | 471,004 | 227,518 | 292,022 |
| P/E ratio | 76 x | 170 x | -717 x | 51.9 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 9.25 x | 10.1 x | 3.63 x | 3.56 x |
| EV / Revenue | 8.16 x | 8.03 x | 2.77 x | 3.11 x |
| EV / EBITDA | 92.1 x | 100 x | 43.2 x | 52.2 x |
| EV / FCF | -83.6 x | -43.2 x | - | 200 x |
| FCF Yield | -1.2% | -2.32% | - | 0.5% |
| Price to Book | 4.43 x | 3.28 x | 1.61 x | 1.76 x |
| Nbr of stocks (in thousands) | 108,887 | 138,892 | 138,892 | 138,892 |
| Reference price 2 | 4,235 | 4,250 | 2,150 | 2,410 |
| Announcement Date | 21/03/19 | 18/03/20 | 20/03/24 | 20/03/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2022 | 2023 |
|---|---|---|---|---|
| Net sales 1 | 49,865 | 58,623 | 82,197 | 93,907 |
| EBITDA 1 | 4,416 | 4,709 | 5,266 | 5,595 |
| EBIT 1 | 2,570 | 2,604 | 2,981 | 3,037 |
| Operating Margin | 5.15% | 4.44% | 3.63% | 3.23% |
| Earnings before Tax (EBT) 1 | 3,656 | 3,837 | -1,255 | 6,731 |
| Net income 1 | 6,065 | 3,051 | -388.1 | 6,455 |
| Net margin | 12.16% | 5.2% | -0.47% | 6.87% |
| EPS 2 | 55.70 | 25.00 | -3.000 | 46.48 |
| Free Cash Flow 1 | -4,864 | -10,906 | - | 1,460 |
| FCF margin | -9.75% | -18.6% | - | 1.55% |
| FCF Conversion (EBITDA) | - | - | - | 26.09% |
| FCF Conversion (Net income) | - | - | - | 22.61% |
| Dividend per Share | - | - | - | - |
| Announcement Date | 21/03/19 | 18/03/20 | 20/03/24 | 20/03/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2022 | 2023 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | 54,464 | 119,288 | 71,100 | 42,708 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | -4,864 | -10,906 | - | 1,460 |
| ROE (net income / shareholders' equity) | 6.01% | 2.15% | - | 3.44% |
| ROA (Net income/ Total Assets) | 1.43% | 1.06% | - | 0.83% |
| Assets 1 | 422,856 | 287,467 | - | 774,394 |
| Book Value Per Share 2 | 955.0 | 1,297 | 1,332 | 1,370 |
| Cash Flow per Share 2 | 124.0 | 134.0 | 32.10 | 8.950 |
| Capex 1 | 2,546 | 8,176 | 8,382 | 12,384 |
| Capex / Sales | 5.11% | 13.95% | 10.2% | 13.19% |
| Announcement Date | 21/03/19 | 18/03/20 | 20/03/24 | 20/03/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -14.52% | 207M | |
| +15.37% | 41.97B | |
| +22.56% | 22.34B | |
| +15.56% | 15.25B | |
| +16.53% | 14B | |
| +49.78% | 12.06B | |
| -10.77% | 6.8B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +14.18% | 5.49B |
- Stock Market
- Equities
- A058820 Stock
- Financials CMG Pharmaceutical Co., Ltd.
